GlassScriptPhysician profile
Erin Anne Masters
NPI 1760697411
$2,756.20
in general payments reported to CMS, 2019-2025
33 companies · $759 in 2025
The $759 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.66 · 2022: $360 · 2023: $798 · 2024: $802 · 2025: $759.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,343 · Entertainment: $16.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.55 |
| Entertainment | $16.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $457.98 | 2021-2025 | |
| Lilly USA, LLC | $335.24 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $225.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $220.18 | 2023-2025 | |
| Amgen INC. | $204.15 | 2023-2025 | Evenity, Otezla, Repatha |
| Eisai INC. | $165.98 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $145.51 | 2023-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.19 | 2023-2025 | Jardiance |
| Abbott Laboratories | $91.91 | 2022-2025 | Freestyle Libre 3 |
| Corium, LLC | $69.86 | 2022-2023 | Adlarity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.55 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $61.68 | 2024-2025 | Breztri |
| Edwards Lifesciences Corporation | $60.44 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Dexcom, INC. | $55.46 | 2023-2024 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $45.35 | 2023-2024 | Trelegy Ellipta |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $45.13 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $36.39 | 2022 | |
| Seqirus USA INC | $33.52 | 2025 | Flucelvax, Fluad |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.26 | 2024-2025 | Caplyta |
| Medtronic, INC. | $29.86 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.41 | 2023 | Evkeeza |
| Biohaven Pharmaceutical Holding Company LTD. | $23.75 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.25 | 2022 | |
| Sumitomo Pharma America, INC. | $21.82 | 2024 | Gemtesa |
| Exact Sciences Corporation | $19.87 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $19.50 | 2022 | |
| Lundbeck LLC | $17.78 | 2024 | Rexulti |
| Biogen, INC. | $17.76 | 2021 | |
| Optos, INC. | $16.35 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Baxter Healthcare | $16.01 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Philips North America LLC | $14.57 | 2024 | (Ck6) Holter |
| Shield Therapeutics INC | $14.18 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.56 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.